Core Insights - Ascentage Pharma announced promising results from a Phase Ib study of olverembatinib for treating succinate dehydrogenase (SDH) deficient gastrointestinal stromal tumors (GIST), marking it as the largest prospective clinical trial for this rare tumor subtype to date [2][4][9] Company Overview - Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [12] - The company has a diverse pipeline, including olverembatinib, a third-generation BCR::ABL1 inhibitor approved in China for specific types of chronic myeloid leukemia [13] Clinical Study Details - The Phase Ib study (NCT03594422) involved 66 patients, including 26 with SDH-deficient GIST, showing an objective response rate (ORR) of 23.1% and a clinical benefit rate (CBR) of 84.6% [4][5] - The median progression-free survival (mPFS) for patients with SDH-deficient GIST was reported at 25.7 months [4][9] Mechanism of Action - Olverembatinib was found to modulate lipid metabolism, inhibiting CD36 expression, which is linked to the uptake of exogenous lipids in tumor cells [6][7] - The study established a novel connection between SDH deficiency and lipid metabolism dysregulation, highlighting the drug's unique mechanism compared to traditional therapies [6][7] Future Directions - Ascentage Pharma plans to continue clinical development for olverembatinib, with ongoing studies to validate its efficacy and safety in SDH-deficient GIST patients [9][10] - The drug has received Breakthrough Therapy Designation from China's National Medical Products Administration for this indication [10]